Gang Chen

Supplementary Data1 from Anti–LAG-3 Antibody LBL-007 plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial

Dongchen Sun, Gang Chen, Yu Zhen Chen, Song Qu et autres

Supplementary material

Data from Anti–LAG-3 Antibody LBL-007 plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial

Dongchen Sun, Gang Chen, Yu Zhen Chen, Song Qu et autres

AbstractPurpose: Prior studies reported synergistic antitumor activity by dual inhibition of lymphocyte activation gene-3 (LAG-3) and PD-1. This study investigated the activity, safety, and biomarker of LAG-3/PD-1 co-blockade plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Patients and …

Protocol1 from Anti–LAG-3 Antibody LBL-007 plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial

Dongchen Sun, Gang Chen, Yu Zhen Chen, Song Qu et autres

Protocol

An affirmative answer to a question on connectivity of p-subgroup posets with irreducible characters

Gang Chen, Wenhua Zhao

Let $p$ be a prime, $e$ a nonnegative integer, and G a finite p-group with $p^{e+1}$ dividing $|G|$. Let I be the intersection of all subgroups of order $p^{e+1}$ in $G$. It is proved that $|I\cap Z(G)|\le |π_0(Γ_{p,e}(G))|\le {\rm Irr}(I)$, where $Γ_{p,e}(G)$, …

An affirmative answer to a question on connectivity of p-subgroup posets with irreducible characters

Gang Chen, Wenhua Zhao

Let $p$ be a prime, $e$ a nonnegative integer, and G a finite p-group with $p^{e+1}$ dividing $|G|$. Let I be the intersection of all subgroups of order $p^{e+1}$ in $G$. It is proved that $|I\cap Z(G)|\le |π_0(Γ_{p,e}(G))|\le {\rm Irr}(I)$, where $Γ_{p,e}(G)$, …

Anti–LAG-3 Antibody LBL-007 plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial

Dongchen Sun, Gang Chen, Yu Chen, Song Qu et autres

PURPOSE: Prior studies reported synergistic antitumor activity by dual inhibition of lymphocyte activation gene-3 (LAG-3) and PD-1. This study investigated the activity, safety, and biomarker of LAG-3/PD-1 co-blockade plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). PATIENTS AND …

cn, gb (code pays fourni par la source)

Investigation of the gastric toxicity induced by exposure to tri-isobutyl phosphate

Zepeng Dong, Wenhao Lin, Jiahao Wang, Changchun Ye et autres

Tri-isobutyl phosphate (TiBP), a widely used organophosphate flame retardant, has attracted increasing attention due to its environmental persistence and potential health risks. However, its impact on gastric function remains unclear. In this study, TiBP concentrations were significantly higher in the serum of …

cn (code pays fourni par la source)

Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA

Chetan Huded, John A. Spertus, Philip G. Jones, Sean M. O’Brien et autres

BACKGROUND: In ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches), an invasive strategy demonstrated better health status outcomes than a conservative strategy in patients with chronic coronary disease (CCD). Some previous studies have shown greater health status benefits …

us, nz (code pays fourni par la source)

Anhedonia and depressive symptoms in adolescent university students from china: the mediating role of early perceive stress

Taipeng Sun, Pan Liu, Yan Ren, 直子 眞﨑 et autres

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has caused increased psychological problems in Group-living people, such as university students. The current epidemic of COVID-19 has become the new normal. The more tailored approach focused on Triggers and key points of emotion regulation …

cn (code pays fourni par la source)

Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study

Yaxiong Zhang, Yan Huang, Yunpeng Yang, Yuanyuan Zhao et autres

Iparomlimab and tuvonralimab (QL1706), a bifunctional anti-programmed death-1/cytotoxic T-lymphocyte antigen-4 antibody, in combination with bevacizumab and doublet chemotherapy was tolerable and showed preliminary antitumor activity in advanced non-small cell lung cancer (NSCLC) in DUBHE-L-201 study. Here, we report the updated data of …

cn (code pays fourni par la source)

Long-term left ventricular ejection function in fulminant and non-fulminant myocarditis: A multicenter study in China

Guangling Li, Jing Zhang, Xu Zheng, Yaogui Ning et autres

Background: There is a gap regarding comparisons of left ventricular ejection fraction (LVEF) changes between fulminant myocarditis (FM) and non-FM (NFM) patients at different follow-up intervals. Methods: This multicenter retrospective study included 324 patients (163 FM and 161 NFM) with confirmed acute …

cn (code pays fourni par la source)

Phase I Clinical Trial of CVL218, a Novel PARP1/2 Inhibitor, in Patients with Advanced Solid Tumors

Zihong Chen, Gang Chen, Yuxiang Ma, Hongyun Zhao et autres

CVL218, a novel poly ADP-ribose polymerase (PARP1/2) inhibitor, has strong PARP1/2 selective inhibitory activity and high oral bioavailability. We aimed to assess the safety and tolerability of CVL218 in patients with pretreated advanced solid tumors. Patients in this phase I dose escalation …

cn (code pays fourni par la source)